ASX:TLXBiotechs
Telix Pharmaceuticals (ASX:TLX) Valuation After Key ProstACT Phase 3 Progress and Prostate Cancer Platform Updates
Telix Pharmaceuticals (ASX:TLX) has caught investor attention after confirming it has wrapped up Part 1 of its pivotal ProstACT Phase 3 trial and already started dosing patients in Part 2 globally.
See our latest analysis for Telix Pharmaceuticals.
Even with this steady clinical and commercial progress, Telix’s 1 month share price return of minus 15.93 percent and year to date share price return of minus 50.42 percent show momentum has cooled. However, the 5 year total shareholder return of...